X
[{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen ApS","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Control of Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP\u00ae Biomarker Patents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics To Present a Dovitinib-DRP\u00ae e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Presents Dovitinib Survival Data from DRP\u00ae Screened RCC Patients at ESMO 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Ends License Agreement for Cancer Drug with Allarity Therapeutics for Lack of Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals for Dovitinib
Filters
Companies By Therapeutic Area
Details:
The agreement provided Allarity with TKI258 (dovitinib), an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors, for the treatment of renal cancer.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Allarity Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Termination
February 02, 2024
Details:
Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Lead Product(s):
Dovitinib ,Stenoparib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 20, 2023
Details:
The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®.
Lead Product(s):
Dovitinib ,Stenoparib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 02, 2022
Details:
Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 15, 2022
Details:
NDA is supported by Allarity’s previously-filed pre-market approval submission to the FDA for the Dovitinib-DRP® companion diagnostic to select RCC patients most likely to respond to the drug.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 22, 2021
Details:
Under the terms of the agreement, Lonza will leverage its capabilities for commercial manufacturing of small-molecules including Dovitinib and oral solid dosage forms to provide Allarity with cGMP compliant drug product supply and regulatory support towards commercialization.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Lonza Group
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
September 23, 2021
Details:
Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with sorafenib.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 16, 2021
Details:
Allarity’s unique and clinically validated DRP® biomarker technology makes it possible to predict whether a particular cancer patient is likely to benefit from treatment with dovitinib, in addition to a broad range of anti-cancer drugs.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 05, 2021
Details:
Allarity’s focus on pediatric osteosarcoma development is based on the results of two previously reported preclinical studies in which treatment with dovitinib, compared to control treatment (sucrose solution lacking dovitinib).
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Oncoheroes Biosciences
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 14, 2021
Details:
The e-Poster provides new details of the Dovitinib-DRP® companion diagnostic, which is used to select cancer patients most likely to respond to the pan-targeted kinase inhibitor (pan-TKI) dovitinib.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 29, 2021